A
Allotera Therapeutics
Developing off-the-shelf cellular therapies for cancer
About Allotera Therapeutics
Wugen is a biotechnology startup that operates in the healthcare sector, specifically in the development of off-the-shelf cell therapies. The company's primary focus is on creating treatments for challenging hematologic cancers, such as Acute Myeloid Leukemia (AML) and T-ALL/LBL. Hematologic cancers are types of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system.
Read full description
Wugen's business model revolves around the research, development, and commercialization of its proprietary cell therapies. These therapies, WU-NK-101 and WU-CART-007, are allogeneic, meaning they are derived from donor cells rather than the patient's own cells. This approach allows for the therapies to be produced in large quantities and readily available for patients, hence the term "off-the-shelf".
The company generates revenue through the clinical trials and eventual sales of its therapies. Currently, Wugen is in the clinical trial phase for both WU-NK-101 and WU-CART-007. The former is in its first-in-human Phase 1 trial, aiming to assess its safety and tolerability in AML patients. The latter has shown promising initial data from its first-in-human Phase 1/2 trial, demonstrating low incidence of high-grade CRS and immune-related adverse events in patients with R/R T-ALL/LBL.
Wugen's primary clients are patients suffering from hematologic cancers, with its market spanning the global healthcare sector. The company's advancements in cell therapy research and development position it as a potential leader in the field of hematologic cancer treatment.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- St. Louis, United States
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 29.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Allotera Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2025 | $115M | $860M | Tybourne Capital Management · Aisling Capital · Lightchain Capital · Fidelity Investments | ↗ |
| SERIES BOther financing | Jul 2021 | $172M | $688M | Alpha Wave Global · RiverVest Venture Partners · Alexandria Venture Investments · Velosity Capital | — |
Growth signals
Latest recorded traffic for Allotera Therapeutics is 4K monthly website visits, up 110.5% over the last three months. Allotera Therapeutics's team declined 17.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Abingworth
Tybourne Capital Management
Alpha Wave Global
RiverVest Venture Partners
Alexandria Venture Investments
Velosity Capital
Intermediate Capital Group
Fidelity Investments
Aisling Capital- LCLYZZ Capital
- LCLightchain Capital
Other known investors1 additional known investor
Washington University in St. Louis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allotera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allotera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.